Trazodone generates m-CPP: In 2008 risks from m-CPP might outweigh benefits of trazodone

World Journal of Biological Psychiatry

Volumn 10, Issue 4 PART 2, 2009, Pages 682-685

  Kast, Richard E ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

Anxiety; Fibrosis; Inflammation; M CPP; Trazodone

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; TRAZODONE; 1-(3-CHLOROPHENYL)PIPERAZINE; ANTIDEPRESSANT AGENT; PIPERAZINE DERIVATIVE; SEROTONIN 2B RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN AGONIST;

DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; DRUG SAFETY; DRUG STRUCTURE; HUMAN; NONHUMAN; RISK FACTOR; SHORT SURVEY; SLEEP; ANIMAL; ANXIETY; ARTICLE; BIOTRANSFORMATION; BLOOD; BRAIN; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; DRUG TOXICITY; MOUSE; PANIC; PATHOPHYSIOLOGY; PHYSIOLOGY; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANXIETY; BIOTRANSFORMATION; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOXICITY; HUMANS; MICE; PANIC; PIPERAZINES; RECEPTOR, SEROTONIN, 5-HT2B; RECEPTOR, SEROTONIN, 5-HT2C; RISK FACTORS; SEROTONIN AGONISTS; STRUCTURE-ACTIVITY RELATIONSHIP; TRAZODONE;

EID: 77449159717     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.1080/15622970902836022     Document Type: Short Survey

References (31)

1. Bagdy G, Graf M, Anheuer ZE, Modos EA, Kantor S. 2001. Anxiety-like effects induced by acute fluoxetine, sertraline or m-CPP treatment are reversed by pretreatment with the 5-HT2C receptor antagonist SB-242084 but not the 5-HT1A receptor antagonist WAY-100635. Int J Neuropsychopharma-col 4:399-408
2. Barbhaiya RH, Buch AB, Greene DS. 1996. Single and multiple dose pharmacokinetics of nefazodone in subjects classified as extensive and poor metabolizers of dextromethorphan. Br J Clin Pharmacol 42(5):573-581.
3. Dykens JA, Jamieson JD, Marroquin LD, Nadanaciva S, Xu JJ, Dunn MC, et al. 2008. In vitro assessment of mitochondrial dysfunction and cytotoxicity of nefazodone, trazodone, and buspirone. Toxicol Sci 103(2):335-345
4. Feuchtl A, Bagli M, Stephan R, Frahnert C, Kolsch H, Kühn KU, et al. 2004. Pharmacokinetics of m-chlorophenylpiperazine after intravenous and oraladministration in healthy male volunteers: implication for the pharmacodynamic profile. Pharmacopsychiatry 37:180-188.
5. Flanagan SR, Greenwald B, Wieber S. 2007. Pharmacological treatment of insomnia for individuals with brain injury. J Head Trauma Rehabil 22(1):67-70.
6. Gijsman HJ, Van Gerven JM, Tieleman MC, Schoemaker RC, Pieters MS, Ferrari MD, et al. 1998. Pharmacokinetic and pharmacodynamic profile of oral and intravenous meta-chlorophenylpiperazine in healthy volunteers. J Clin Psycho-pharmacol 18:289-295.
7. Gornemann T, Hübner H, Gmeiner P, Horowski R, Latte KP, Flieger M, et al. 2008. Characterization of the molecular fragment that is responsible for agonism of pergolide at serotonin 5-hydroxytryptamine 2B and 5-hydroxytryptamine 2A receptors. J Pharmacol Exp Ther 324:1136-1145.
8. Harada K, Aota M, Inoue T, Matsuda R, Mihara T, Yamaji T, et al. 2006. Anxiolytic activity of a novel potent serotonin 5-HT2C receptor antagonist FR260010: a comparison with diazepam and buspirone. Eur J Pharmacol 553:171-184.
9. Johanson CE, Kilbey M, Gatchalian K, Tancer M. 2006. Discriminative stimulus effects of 3,4-methylenedioxymetham-phetamine (MDMA) in humans trained to discriminate among d-amphetamine, m-chlorophenylpiperazine and placebo. Drug Alcohol Depend 81:27-36.
10. Junghanns S, Fuhrmann JT, Simonis G, Oelwein C, Koch R, Strasser RH, et al. 2007. Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: a reader-blinded monocenter echocardiography study. Mov Disord 22:234-238 (Pubitemid 46374768)
11. Kast RE. 2007. Are we done with trazodone? The potential for damage by mCPP-a metabolite of trazodone. Acta Neurop-sychiatr 19:220-221.
12. Kast RE, Altschuler EL. 2007. Dopamine agonists and valvular heart disease. New Engl J Med 356:1677.
13. Khaliq S, Irfan B, Haider S, Haleem DJ. 2008. m-CPP induced hypolocomotion does not interfere in the assessment of memory functions in rats. Pak J Pharm Sci 21:139-143.
14. Kovaleva J, Devuyst E, De Paepe P, Verstraete A. 2008. Acute-chlorophenylpiperazine overdose: a case report and review of the literature. Ther Drug Monit 30:394-398.
15. Launay JM, Herve P, Peoc'h K, Tournois C, Callebert J, Nebigil CG, et al. 2002. Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat Med 8(10):1129-1135. (Pubitemid 35175968)
16. Matsumoto K, Yobimoto K, Huong NT, Abdel-Fattah M, Van Hien T, Watanabe H. 1999. Psychological stress-induced enhancement of brain lipid peroxidation via nitric oxide systems and its modulation by anxiolytic and anxiogenic drugs in mice. Brain Res 839(1):74-84.
17. Mercolini L, Colliva C, Amore M, Fanali S, Raggi MA. 2008. HPLC analysis of the antidepressant trazodone and its main metabolite m-CPP in human plasma. J Pharm Biomed Anal 47:882-887.
18. Michel TM, Camara S, Tatschner T, Frangou S, Sheldrick AJ, Riederer P, et al. 2008. Increased xanthine oxidase in the thalamus and putamen in depression. World J Biol Psychiatry 12:1-7.
19. Mizoguchi Y, Monji A. 2005. Low-dose-trazodone-induced disorganized type psychosis. J Neuropsychiatry Clin Neurosci 17:253-254.
20. Munizza C, Olivieri L, Di Loreto G, Dionisio P. 2006. A comparative, randomized, double-blind study of trazodone prolonged-release and sertraline in the treatment of major depressive disorder. Curr Med Res Opin 22:1703-1713.
21. Nunes-de-Souza V, Nunes-de-Souza RL, Rodgers RJ, Canto-de-Souza A. 2008. 5-HT2 receptor activation in the midbrain periaqueductal grey (PAG) reduces anxiety-like behaviour in mice. Behav Brain Res 187:72-79.
22. Pandi-Perumal SR, Trakht I, Srinivasan V, Spence DW, Poeggeler B, Hardeland R, et al. 2008. The effect of melatonergic and non-melatonergic antidepressants on sleep: weighing the alternatives. World J Biol Psychiatry 4:1-13 [Epub ahead of print].
23. Patel BN, Sharma N, Sanyal M, Shrivastav PS. 2008. High throughput and sensitive determination of trazodone and its primary metabolite, m-chlorophenylpiperazine, in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Anal Technol Biomed Life Sci 871(1):44-54.
24. Qaseem A, Snow V, Denberg TD, Forciea MA, Owens DK. 2008. Clinical Efficacy Assessment Subcommittee of American College of Physicians. Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of Physicians. Ann Intern Med 149(10):725-733.
25. Roth T 2009. Hypnotic use for insomnia management in chronic obstructive pulmonary disease. Sleep Med 10(1):19-25.
26. Ruddell RG, Oakley F, Hussain Z, Yeung I, Bryan-Lluka LJ, Ramm GA. 2006. A role for serotonin (5-HT) in hepatic stellate cell function and liver fibrosis. Am J Pathol 169:861-876.
27. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. 2007. Dopamine agonists and the risk of cardiac-valve regurgitation. New Engl J Med 356:29-38.
28. Schneider B, Pietri M, Mouillet-Richard S, Ermonval M, Mutel V, Launay JM, et al. 2006. Control of bioamine metabolism by 5-HT2B and alpha 1D autoreceptors through reactive oxygen species and tumor necrosis factor-alpha signaling in neuronal cells. Ann NY Acad Sci 1091:123-141.
29. Staack RF, Paul LD, Schmid D, Roider G, Rolf B. 2007. Proof of a 1-(3-chlorophenyl)piperazine (mCPP) intake: use as adulterant of cocaine resulting in drug-drug interactions? J Chromatogr B Anal Technol Biomed Life Sci 855:127-133.
30. Varcoe TJ, Kennaway DJ. 2008. Activation of 5-HT2C receptors acutely induces Per1 gene expression in the rat SCN in vitro. Brain Res 1209:19-28.
31. Van Veen JF, Van der Wee NJ, Fiselier J, Van Vliet IM, Westenberg HG. 2007. Behavioural effects of rapid intravenous administration of meta-chlorophenylpiperazine (m-CPP) in patients with generalized social anxiety disorder, panic disorder and healthy controls. Eur Neuropsychopharmacol 17(10):637-642.